Triple negative breast cancer (TNBC) is defined by absent expression of ER, PR, and HER2. According to the CREATE-X trial, what systemic therapy improved disease-free survival in TNBC patients with residual disease after neoadjuvant chemotherapy?

• A Olaparib
• B Pembrolizumab
• C Pertuzumab
• D Capecitabine ✓

Explanation

The CREATE-X trial demonstrated that adjuvant capecitabine for 8 cycles significantly improved 5-year disease-free survival (74% vs 68%) and overall survival (79% vs 71%) in patients who had residual invasive disease after neoadjuvant chemotherapy, with the greatest benefit in TNBC. Olaparib is used in BRCA-mutated HER2-negative breast cancer (OlympiA trial). Pembrolizumab is given as neoadjuvant/adjuvant in high-risk TNBC per KEYNOTE-522.

Reference: Bailey & Love's Short Practice of Surgery, 27th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.